Trimel Announces New TriVair(TM) Website

TORONTO, ONTARIO--(Marketwired - July 31, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair™. Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair™ is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.

About Trimel

Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health, and respiratory medicine. Natesto™, a product utilizing Trimel's licensed nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.

Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536
[e-mail]
www.trimelpharmaceuticals.com